Why the study?
To provide updated model-based estimates of the net balance in benefits and harms from routine low-dose aspirin use for primary prevention, supporting the USPSTF recommendation update.
Does routine use of low-dose aspirin improve lifetime net QALYs and life-years in adults aged 40 to 79 years without prior CVD?
Population
Hypothetical US cohorts aged 40 to 79 years with up to 20% 10-year CVD risk and no prior CVD
Comparison
Low-dose aspirin for lifetime use or with stopping ages from 65 to 85 years
Design
Microsimulation modeling study
Follow-up
Lifetime
Authors
Loading...
Supports aspirin initiation at ages 40-59 with ≥5% 10-year CVD risk; extends RCT data via lifetime microsimulation.
Does routine use of low-dose aspirin improve lifetime net QALYs and life-years in adults aged 40 to 79 years without prior CVD?
Microsimulation modeling suggests low-dose aspirin for primary prevention provides net lifetime benefits primarily for persons starting at younger ages (40-59 years) with higher 10-year CVD risk.
Dehmer et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: